The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...
TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback